AFP and hepatocellular carcinoma: At a cut-off level of 5.0 ng/dl, AFP was able to differentiate between HCC cases and the 2 control groups with 80% sensitivity, 90% specificity, 75% NPV, 92.3% PPV and 84% efficacy.